Trial · NCT00573430

ARIA (Atacand Renoprotection In NephropAthy Pt.)

NCT00573430, Phase 4, Completed, AstraZeneca; results first posted 2011-07-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. ARIA (Atacand Renoprotection In NephropAthy Pt.). Trials, record NCT00573430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00573430

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: ARIA (Atacand Renoprotection In NephropAthy Pt.)
NCT number: NCT00573430
Status: Completed
Phases: Phase 4
Enrollment: 128 participants, actual
Lead sponsor: AstraZeneca
Conditions: Non-diabetic Nephropathy With Hypertension
Interventions: Candesartan Cilexetil, Candesartan Cilexetil, Candesartan Cilexetil 32mg
First posted: 2007-12-14
Last updated: 2011-08-23
Results first posted: 2011-07-19

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks	baseline to 28 weeks	Decrease of urinary protein/creatinine ratio means improvement of renal disease.
Secondary	Change of Systolic and Diastolic Blood Pressure From Baseline	baseline to 28 weeks
Secondary	Inflammatory Marker (Hs-C-peptide Reactive Protein)	baseline to 28 weeks	To evaluate how to reduce and relate with cardiovascular risk
Secondary	Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation	28 weeks	GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African-American) (conventional units)
Secondary	Treatment-emergent Adverse Events	Baseline to 28 weeks	Prevalence of adverse events after treatment regardless causality. An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition from the signing of the informed consent, whether or not considered causally related to the product.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks	baseline to 28 weeks	mg/g	MEAN
SECONDARY	Change of Systolic and Diastolic Blood Pressure From Baseline	baseline to 28 weeks	mmHg	MEAN
SECONDARY	Inflammatory Marker (Hs-C-peptide Reactive Protein)	baseline to 28 weeks	mg/dL	MEAN
SECONDARY	Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation	28 weeks	mL/min/1.73 m2	MEAN
SECONDARY	Treatment-emergent Adverse Events	Baseline to 28 weeks	Participants	NUMBER

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks	Candesartan 8 mg		794.0	Standard Deviation 1,070.10	mg/g
The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks	Candesartan 16mg		639.9	Standard Deviation 863.30	mg/g
The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks	Candesartan 32mg		819.0	Standard Deviation 823.60	mg/g
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 8 mg	Systolic	-11.70	Standard Deviation 14.90	mmHg
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 16mg	Systolic	-13.30	Standard Deviation 14.90	mmHg
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 32mg	Systolic	-16.10	Standard Deviation 17.30	mmHg
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 8 mg	Diastolic	-8.90	Standard Deviation 13.30	mmHg
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 16mg	Diastolic	-8.00	Standard Deviation 13.30	mmHg
Change of Systolic and Diastolic Blood Pressure From Baseline	Candesartan 32mg	Diastolic	-13.00	Standard Deviation 14.70	mmHg
Inflammatory Marker (Hs-C-peptide Reactive Protein)	Candesartan 8 mg		0.01	Standard Deviation 0.12	mg/dL

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Candesartan 8 mg	40
Overall Study	STARTED	Candesartan 16mg	45
Overall Study	STARTED	Candesartan 32mg	43
Overall Study	COMPLETED	Candesartan 8 mg	39
Overall Study	COMPLETED	Candesartan 16mg	40
Overall Study	COMPLETED	Candesartan 32mg	33
Overall Study	NOT COMPLETED	Candesartan 8 mg	1
Overall Study	NOT COMPLETED	Candesartan 16mg	5
Overall Study	NOT COMPLETED	Candesartan 32mg	10

Source ClinicalTrials.gov

Adverse events21

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	Candesartan 8 mg	4	40
other	Nasopharyngitis	Infections and infestations	Candesartan 16mg	2	45
other	Nasopharyngitis	Infections and infestations	Candesartan 32mg	5	43
other	Dizziness	Nervous system disorders	Candesartan 8 mg	2	40
other	Dizziness	Nervous system disorders	Candesartan 16mg	2	45
other	Dizziness	Nervous system disorders	Candesartan 32mg	3	43
other	Headache	Nervous system disorders	Candesartan 8 mg	2	40
other	Headache	Nervous system disorders	Candesartan 16mg	2	45
other	Headache	Nervous system disorders	Candesartan 32mg	0	43
other	Cough	Respiratory, thoracic and mediastinal disorders	Candesartan 8 mg	3	40

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Candesartan 8 mg
Total, all-cause mortality	Candesartan 16mg
Total, all-cause mortality	Candesartan 32mg
Total, other adverse events	Candesartan 8 mg	11	40
Total, other adverse events	Candesartan 16mg	6	45
Total, other adverse events	Candesartan 32mg	9	43
Total, serious adverse events	Candesartan 8 mg	0	40
Total, serious adverse events	Candesartan 16mg	1	45
Total, serious adverse events	Candesartan 32mg	1	43

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00573430

GET https://conductscience.org/api/trials/v1/NCT00573430/events?page=2

API reference For AI assistants